Cargando…
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the other histological types of lung cancer. The predominant neu...
Autores principales: | Wojcik, Ewa, Kulpa, Jan Kanty |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716401/ https://www.ncbi.nlm.nih.gov/pubmed/29238236 http://dx.doi.org/10.2147/LCTT.S149516 |
Ejemplares similares
-
Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma
por: Cheng, Yizhuang, et al.
Publicado: (2019) -
Utility of the Serum ProGRP Level for Follow-up of Pulmonary Carcinoid Tumors
por: Taira, Naohiro, et al.
Publicado: (2014) -
ProGRP与NSE对小细胞肺癌诊断价值的meta分析
Publicado: (2010) -
Detection of CEA and ProGRP Levels in BALF of Patients with Peripheral Lung Cancer and Their Relationship with CT Signs
por: Tian, Kui, et al.
Publicado: (2022) -
Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm
por: Rosiek, Violetta, et al.
Publicado: (2023)